Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral S-ketamine pilot study for depression or demoralization in advanced cancer palliative care
NL-OMON29195Phase 2Not yet recruiting
- Sponsor
- Investigator-initiated
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of esketamine in major depressive disorder (MDD) and cancer, sponsored by Investigator-initiated. Primary endpoints: Decrease in depression symptom severity, Decrease in demoralization severity and 10 more. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)cancer
Beyond the preview
Go deeper on NL-OMON29195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29195.